Press Contact
Ellen Mullally
Phone: 410-992-3124
Email: emullally@paltmed.org
JAMDA
December 2, 2021
Showing 3061 - 3070 of 8234 results
JAMDA
December 1, 2021
Comparing Virtual to In-Person Delivery of Continuing Medical Education in Dementia Care: Which Is Preferred?
There is limited understanding of learners’ perceptions of virtual learning during the COVID-19 pandemic, as well as the use of virtual modalities for interprofessional education (IPE) in primary care. Four of 7 in-person annual “Booster Day” IPE sessions for health professionals working in primary care–ba...
JAMDA
November 30, 2021
Independent, Differential Effects of Delirium on Disability and Mortality Risk After Hip Fracture
To assess the independent effect of delirium on mortality and disability after 1 year of follow-up, in consecutive older patients with hip fracture hospitalized for surgical repair.
JAMDA
November 30, 2021
Standardized, Coordinated Care in Nursing Homes Lowers Rehospitalization After Hip Fracture
To assess the effect of enhanced standardized interdisciplinary cooperation between the orthogeriatric ward, municipality, and nursing home facility (NHF) on readmission rates in patients with hip fracture.
JAMDA
November 30, 2021
Preoperative Deprescribing for Medical Optimization of Older Adults Undergoing Surgery: A Systematic Review
To summarize the evidence for preoperative deprescribing and its effect on postoperative outcomes in older adults undergoing surgery.
JAMDA
November 30, 2021
Effectiveness of Comanagement Model: Geriatric Medicine and Vascular Surgery
Older surgical patients frequently develop postoperative complications due to their frailty and multiple comorbidities. Geriatric medicine consultation helps to optimize risk factors and improve outcomes in patients with hip fracture. This study aimed to evaluate patient outcomes before and after comanagem...
JAMDA
November 29, 2021
Effectiveness and Tolerance of Renin-Angiotensin System Inhibitors With Aging in Chronic Kidney Disease
Renin-angiotensin system inhibitors (RASi) are recommended for slowing chronic kidney disease (CKD) progression to kidney failure. Their effectiveness and tolerance as patients age remain uncertain because older patients have often been excluded from clinical trials.
Podcast
November 29, 2021
FMDA | Nursing Home Staffing Perils
JAMDA
November 29, 2021
Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial
Preclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.
JAMDA
November 27, 2021